Genetic pain loss disorders.

Cox, J. J., Woods, C. G. & Kurth, I. Peripheral sensory neuropathies–pain loss vs. pain gain. Med. Genet. 32, 233–241 (2020).

Rotthier, A. et al. Genes for hereditary sensory and autonomic neuropathies: a genotype-phenotype correlation. Brain 132, 2699–2711 (2009).

pubmed: 19651702 pmcid: 2759337

Rotthier, A., Baets, J., Timmerman, V. & Janssens, K. Mechanisms of disease in hereditary sensory and autonomic neuropathies. Nat. Rev. Neurol. 8, 73–85 (2012).

pubmed: 22270030

Nicholson, G. A. SPTLC1-Related Hereditary Sensory Neuropathy. GeneReviews [online] https://www.ncbi.nlm.nih.gov/books/NBK1390/ (updated 2 Dec 2021).

Schon, K. R. et al. Congenital Insensitivity to Pain Overview. GeneReviews [online] https://www.ncbi.nlm.nih.gov/books/NBK481553/ (updated 11 Jun 2020).

Haga, N., Kubota, M. & Miwa, Z. Epidemiology of hereditary sensory and autonomic neuropathy type IV and V in Japan. Am. J. Med. Genet. A 161A, 871–874 (2013).

pubmed: 23495212

Kurth, I. Hereditary Sensory and Autonomic Neuropathy Type II. GeneReviews [online] https://www.ncbi.nlm.nih.gov/books/NBK49247/ (updated 1 Apr 2021).

Curro, R. et al. RFC1 expansions are a common cause of idiopathic sensory neuropathy. Brain 144, 1542–1550 (2021).

pubmed: 33969391 pmcid: 8262986

Lafreniere, R. G. et al. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the study of Canadian genetic isolates. Am. J. Hum. Genet. 74, 1064–1073 (2004).

pubmed: 15060842 pmcid: 1181970

Dong, J., Edelmann, L., Bajwa, A. M., Kornreich, R. & Desnick, R. J. Familial dysautonomia: detection of the IKBKAP IVS20(+6T –> C) and R696P mutations and frequencies among Ashkenazi Jews. Am. J. Med. Genet. 110, 253–257 (2002).

pubmed: 12116234

Davidson, G. et al. Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. J. Neurol. 259, 1673–1685 (2012).

pubmed: 22302274 pmcid: 3752368

Houlden, H. et al. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain 129, 411–425 (2006).

pubmed: 16364956

Dawkins, J. L., Hulme, D. J., Brahmbhatt, S. B., Auer-Grumbach, M. & Nicholson, G. A. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat. Genet. 27, 309–312 (2001).

pubmed: 11242114

Nicholson, G. A. et al. Hereditary sensory neuropathy type I: haplotype analysis shows founders in southern England and Europe. Am. J. Hum. Genet. 69, 655–659 (2001).

pubmed: 11479835 pmcid: 1235494

Edvardson, S. et al. Hereditary sensory autonomic neuropathy caused by a mutation in dystonin. Ann. Neurol. 71, 569–572 (2012).

pubmed: 22522446

Manganelli, F. et al. Novel mutations in dystonin provide clues to the pathomechanisms of HSAN-VI. Neurology 88, 2132–2140 (2017).

pubmed: 28468842 pmcid: 5447400

Fortugno, P. et al. Recessive mutations in the neuronal isoforms of DST, encoding dystonin, lead to abnormal actin cytoskeleton organization and HSAN type VI. Hum. Mutat. 40, 106–114 (2019).

pubmed: 30371979

Jin, J. Y. et al. Novel compound heterozygous DST variants causing hereditary sensory and autonomic neuropathies VI in twins of a Chinese family. Front. Genet. 11, 492 (2020).

pubmed: 32528525 pmcid: 7262964

Yoshioka, N. et al. Diverse dystonin gene mutations cause distinct patterns of Dst isoform deficiency and phenotypic heterogeneity in Dystonia musculorum mice. Dis. Model Mech. https://doi.org/10.1242/dmm.041608 (2020).

doi: 10.1242/dmm.041608 pubmed: 32482619 pmcid: 7325434

Young, K. G. & Kothary, R. Dystonin/Bpag1–a link to what? Cell Motil. Cytoskeleton 64, 897–905 (2007).

pubmed: 17849487

Young, K. G. & Kothary, R. Dystonin/Bpag1 is a necessary endoplasmic reticulum/nuclear envelope protein in sensory neurons. Exp. Cell Res. 314, 2750–2761 (2008).

pubmed: 18638474

Tseng, K. W., Peng, M. L., Wen, Y. C., Liu, K. J. & Chien, C. L. Neuronal degeneration in autonomic nervous system of Dystonia musculorum mice. J. Biomed. Sci. 18, 9 (2011).

pubmed: 21272373 pmcid: 3038143

Ryan, S. D. et al. Neuronal dystonin isoform 2 is a mediator of endoplasmic reticulum structure and function. Mol. Biol. Cell 23, 553–566 (2012).

pubmed: 22190742 pmcid: 3279385

Ferrier, A., Boyer, J. G. & Kothary, R. Cellular and molecular biology of neuronal dystonin. Int. Rev. Cell Mol. Biol. 300, 85–120 (2013).

pubmed: 23273860

Ferrier, A. et al. Disruption in the autophagic process underlies the sensory neuropathy in Dystonia musculorum mice. Autophagy 11, 1025–1036 (2015).

pubmed: 26043942 pmcid: 4590603

Groves, R. W. et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J. Invest. Dermatol. 130, 1551–1557 (2010).

pubmed: 20164846

Liu, L. et al. Autosomal recessive epidermolysis bullosa simplex due to loss of BPAG1-e expression. J. Invest. Dermatol. 132, 742–744 (2012).

pubmed: 22113475

Brown, A., Bernier, G., Mathieu, M., Rossant, J. & Kothary, R. The mouse dystonia musculorum gene is a neural isoform of bullous pemphigoid antigen 1. Nat. Genet. 10, 301–306 (1995).

pubmed: 7670468

Scott, B. L. et al. Membrane bending occurs at all stages of clathrin-coat assembly and defines endocytic dynamics. Nat. Commun. 9, 419 (2018).

pubmed: 29379015 pmcid: 5789089

Nahorski, M. S. et al. A novel disorder reveals clathrin heavy chain-22 is essential for human pain and touch development. Brain 138, 2147–2160 (2015).

pubmed: 26068709 pmcid: 4511860

Nahorski, M. S. et al. Clathrin heavy chain 22 contributes to the control of neuropeptide degradation and secretion during neuronal development. Sci. Rep. 8, 2340 (2018).

pubmed: 29402896 pmcid: 5799199

Riviere, J. B. et al. KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. Am. J. Hum. Genet. 89, 219–230 (2011).

pubmed: 21820098 pmcid: 3155159

Lee, J. R. et al. De novo mutations in the motor domain of KIF1A cause cognitive impairment, spastic paraparesis, axonal neuropathy, and cerebellar atrophy. Hum. Mutat. https://doi.org/10.1002/humu.22709 (2014).

doi: 10.1002/humu.22709 pubmed: 25265257 pmcid: 4373469

Nemani, T. et al. KIF1A-related disorders in children: a wide spectrum of central and peripheral nervous system involvement. J. Peripher. Nerv. Syst. 25, 117–124 (2020).

pubmed: 32096284

Hirokawa, N. & Tanaka, Y. Kinesin superfamily proteins (KIFs): various functions and their relevance for important phenomena in life and diseases. Exp. Cell Res. 334, 16–25 (2015).

pubmed: 25724902

Okada, Y., Yamazaki, H., Sekine-Aizawa, Y. & Hirokawa, N. The neuron-specific kinesin superfamily protein KIF1A is a unique monomeric motor for anterograde axonal transport of synaptic vesicle precursors. Cell 81, 769–780 (1995).

pubmed: 7539720

Sgro, A. E., Bajjalieh, S. M. & Chiu, D. T. Single-axonal organelle analysis method reveals new protein-motor associations. ACS Chem. Neurosci. 4, 277–284 (2013).

pubmed: 23421679

Hummel, J. J. A. & Hoogenraad, C. C. Specific KIF1A-adaptor interactions control selective cargo recognition. J. Cell Biol. https://doi.org/10.1083/jcb.202105011 (2021).

doi: 10.1083/jcb.202105011 pubmed: 34287616 pmcid: 8298099

Verhoeven, K. et al. Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am. J. Hum. Genet. 72, 722–727 (2003).

pubmed: 12545426 pmcid: 1180247

Houlden, H. et al. A novel RAB7 mutation associated with ulcero-mutilating neuropathy. Ann. Neurol. 56, 586–590 (2004).

pubmed: 15455439

Zhang, K. et al. Defective axonal transport of Rab7 GTPase results in dysregulated trophic signaling. J. Neurosci. 33, 7451–7462 (2013).

pubmed: 23616551 pmcid: 3722856

Ponomareva, O. Y., Eliceiri, K. W. & Halloran, M. C. Charcot-Marie-Tooth 2b associated Rab7 mutations cause axon growth and guidance defects during vertebrate sensory neuron development. Neural Dev. 11, 2 (2016).

pubmed: 26791407 pmcid: 4721196

Lowe, H., Toyang, N., Steele, B., Bryant, J. & Ngwa, W. The endocannabinoid system: a potential target for the treatment of various diseases. Int. J. Mol. Sci. https://doi.org/10.3390/ijms22179472 (2021).

doi: 10.3390/ijms22179472 pubmed: 34502379 pmcid: 8430969

Cravatt, B. F. et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl Acad. Sci. USA 98, 9371–9376 (2001).

pubmed: 11470906 pmcid: 55427

Habib, A. M. et al. Microdeletion in a FAAH pseudogene identified in a patient with high anandamide concentrations and pain insensitivity. Br. J. Anaesth. 123, e249–e253 (2019).

pubmed: 30929760 pmcid: 6676009

Chiang, K. P., Gerber, A. L., Sipe, J. C. & Cravatt, B. F. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum. Mol. Genet. 13, 2113–2119 (2004).

pubmed: 15254019

Mikaeili, H. et al. CRISPR interference at the FAAH-OUT genomic region reduces FAAH expression. Preprint at bioRxiv https://doi.org/10.1101/633396 (2019).

doi: 10.1101/633396

Cravatt, B. F. et al. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc. Natl Acad. Sci. USA 101, 10821–10826 (2004).

pubmed: 15247426 pmcid: 490018

Dincheva, I. et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat. Commun. 6, 6395 (2015).

pubmed: 25731744

Lichtman, A. H., Shelton, C. C., Advani, T. & Cravatt, B. F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109, 319–327 (2004).

pubmed: 15157693

Clapper, J. R. et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 13, 1265–1270 (2010).

pubmed: 20852626 pmcid: 3260554

Klein, C. J. et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat. Genet. 43, 595–600 (2011).

pubmed: 21532572 pmcid: 3102765

Winkelmann, J. et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum. Mol. Genet. 21, 2205–2210 (2012).

pubmed: 22328086 pmcid: 3465691

Baets, J. et al. Defects of mutant DNMT1 are linked to a spectrum of neurological disorders. Brain 138, 845–861 (2015).

pubmed: 25678562 pmcid: 5014076

Chen, Y. C. et al. Transcriptional regulator PRDM12 is essential for human pain perception. Nat. Genet. 47, 803–808 (2015).

pubmed: 26005867 pmcid: 7212047

Inamadar, A. C. et al. Extending the phenotype of midface toddler excoriation syndrome (MiTES): five new cases in three families with PR domain containing protein 12 (PRDM12) mutations. J. Am. Acad. Dermatol. 81, 1415–1417 (2019).

pubmed: 31128170

Landy, M. A., Goyal, M., Casey, K. M., Liu, C. & Lai, H. C. Loss of Prdm12 during development, but not in mature nociceptors, causes defects in pain sensation. Cell Rep. 34, 108913 (2021).

pubmed: 33789102 pmcid: 8048104

Desiderio, S. et al. Prdm12 directs nociceptive sensory neuron development by regulating the expression of the NGF receptor TrkA. Cell Rep. 26, 3522–3536.e5 (2019).

pubmed: 30917309

Bartesaghi, L. et al. PRDM12 is required for initiation of the nociceptive neuron lineage during neurogenesis. Cell Rep. 26, 3484–3492.e4 (2019).

pubmed: 30917305 pmcid: 7676307

Zhang, S. et al. Clinical features for diagnosis and management of patients with PRDM12 congenital insensitivity to pain. J. Med. Genet. 53, 533–535 (2016).

pubmed: 26975306

Habib, A. M. et al. A novel human pain insensitivity disorder caused by a point mutation in ZFHX2. Brain 141, 365–376 (2018).

pubmed: 29253101

Durr, A. et al. Atlastin1 mutations are frequent in young-onset autosomal dominant spastic paraplegia. Arch. Neurol. 61, 1867–1872 (2004).

pubmed: 15596607

Guelly, C. et al. Targeted high-throughput sequencing identifies mutations in atlastin-1 as a cause of hereditary sensory neuropathy type I. Am. J. Hum. Genet. 88, 99–105 (2011).

pubmed: 21194679 pmcid: 3014370

Zhang, H. & Hu, J. Shaping the endoplasmic reticulum into a social network. Trends Cell Biol. 26, 934–943 (2016).

pubmed: 27339937

Leonardis, L., Auer-Grumbach, M., Papic, L. & Zidar, J. The N355K atlastin 1 mutation is associated with hereditary sensory neuropathy and pyramidal tract features. Eur. J. Neurol. 19, 992–998 (2012).

pubmed: 22340599

Fischer, D. et al. A novel missense mutation confirms ATL3 as a gene for hereditary sensory neuropathy type 1. Brain 137, e286 (2014).

pubmed: 24736309

Kornak, U. et al. Sensory neuropathy with bone destruction due to a mutation in the membrane-shaping atlastin GTPase 3. Brain 137, 683–692 (2014).

pubmed: 24459106

Xu, H. et al. ATL3 gene mutation in a Chinese family with hereditary sensory neuropathy type 1F. J. Peripher. Nerv. Syst. 24, 150–155 (2019).

pubmed: 30680846

Cintra, V. P. et al. Rare mutations in ATL3, SPTLC2 and SCN9A explaining hereditary sensory neuropathy and congenital insensitivity to pain in a Brazilian cohort. J. Neurol. Sci. 427, 117498 (2021).

pubmed: 34090020

Novarino, G. et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science 343, 506–511 (2014).

pubmed: 24482476 pmcid: 4157572

Nizon, M. et al. ARL6IP1 mutation causes congenital insensitivity to pain, acromutilation and spastic paraplegia. Clin. Genet. 93, 169–172 (2018).

pubmed: 28471035

Maddirevula, S. et al. Autozygome and high throughput confirmation of disease genes candidacy. Genet. Med. 21, 736–742 (2019).

pubmed: 30237576

Chukhrova, A. L. et al. A new case of infantile-onset hereditary spastic paraplegia with complicated phenotype (SPG61) in a consanguineous Russian family. Eur. J. Neurol. 26, e61–e62 (2019).

pubmed: 30980493

Wakil, S. M. et al. Truncating ARL6IP1 variant as the genetic cause of fatal complicated hereditary spastic paraplegia. BMC Med. Genet. 20, 119 (2019).

pubmed: 31272422 pmcid: 6610916

Cao, Y. et al. Genotype-phenotype study and expansion of ARL6IP1-related complicated hereditary spastic paraplegia. Clin. Genet. 99, 477–480 (2021).

pubmed: 33188530

Kurth, I. et al. Mutations in FAM134B, encoding a newly identified Golgi protein, cause severe sensory and autonomic neuropathy. Nat. Genet. 41, 1179–1181 (2009).

pubmed: 19838196

Falcao de Campos, C. et al. Hereditary sensory autonomic neuropathy type II: report of two novel mutations in the FAM134B gene. J. Peripher. Nerv. Syst. 24, 354–358 (2019).

pubmed: 31596031

Ilgaz Aydinlar, E., Rolfs, A., Serteser, M. & Parman, Y. Mutation in FAM134B causing hereditary sensory neuropathy with spasticity in a Turkish family. Muscle Nerve 49, 774–775 (2014).

pubmed: 24327336

Luo, Z. Y. et al. Late-onset hereditary sensory and autonomic neuropathy type 2B caused by novel compound heterozygous mutations in FAM134B presenting as chronic recurrent ulcers on the soles. Indian. J. Dermatol. Venereol. Leprol. 87, 455 (2021).

pubmed: 33943063

Murphy, S. M., Davidson, G. L., Brandner, S., Houlden, H. & Reilly, M. M. Mutation in FAM134B causing severe hereditary sensory neuropathy. J. Neurol. Neurosurg. Psychiatry 83, 119–120 (2012).

pubmed: 21115472

Wakil, S. M. et al. Exome sequencing: mutilating sensory neuropathy with spastic paraplegia due to a mutation in FAM134B gene. Case Rep. Genet. 2018, 9468049 (2018).

pubmed: 30643655 pmcid: 6311306

Yang, Y. S. & Strittmatter, S. M. The reticulons: a family of proteins with diverse functions. Genome Biol. 8, 234 (2007).

pubmed: 18177508 pmcid: 2246256

Zimmerberg, J. & Kozlov, M. M. How proteins produce cellular membrane curvature. Nat. Rev. Mol. Cell Biol. 7, 9–19 (2006).

pubmed: 16365634

Voeltz, G. K., Prinz, W. A., Shibata, Y., Rist, J. M. & Rapoport, T. A. A class of membrane proteins shaping the tubular endoplasmic reticulum. Cell 124, 573–586 (2006).

pubmed: 16469703

Baumann, O. & Walz, B. Endoplasmic reticulum of animal cells and its organization into structural and functional domains. Int. Rev. Cytol. 205, 149–214 (2001).

pubmed: 11336391

Hubner, C. A. & Kurth, I. Membrane-shaping disorders: a common pathway in axon degeneration. Brain 137, 3109–3121 (2014).

pubmed: 25281866

Hu, J. et al. Membrane proteins of the endoplasmic reticulum induce high-curvature tubules. Science 319, 1247–1250 (2008).

pubmed: 18309084

Muriel, M. P. et al. Atlastin-1, the dynamin-like GTPase responsible for spastic paraplegia SPG3A, remodels lipid membranes and may form tubules and vesicles in the endoplasmic reticulum. J. Neurochem. 110, 1607–1616 (2009).

pubmed: 19573020

Orso, G. et al. Homotypic fusion of ER membranes requires the dynamin-like GTPase atlastin. Nature 460, 978–983 (2009).

pubmed: 19633650

Behrendt, L., Kurth, I. & Kaether, C. A disease causing ATLASTIN 3 mutation affects multiple endoplasmic reticulum-related pathways. Cell Mol. Life Sci. 76, 1433–1445 (2019).

pubmed: 30666337 pmcid: 6420906

Krols, M. et al. Sensory neuropathy-causing mutations in ATL3 affect ER-mitochondria contact sites and impair axonal mitochondrial distribution. Hum. Mol. Genet. 28, 615–627 (2019).

pubmed: 30339187

Krols, M. et al. Sensory-neuropathy-causing mutations in ATL3 cause aberrant ER membrane tethering. Cell Rep. 23, 2026–2038 (2018).

pubmed: 29768202

Yamamoto, Y., Yoshida, A., Miyazaki, N., Iwasaki, K. & Sakisaka, T. Arl6IP1 has the ability to shape the mammalian ER membrane in a reticulon-like fashion. Biochem. J. 458, 69–79 (2014).

pubmed: 24262037

Fowler, P. C. & O’Sullivan, N. C. ER-shaping proteins are required for ER and mitochondrial network organization in motor neurons. Hum. Mol. Genet. 25, 2827–2837 (2016).

pubmed: 27170313

Dong, R. et al. The inositol 5-phosphatase INPP5K participates in the fine control of ER organization. J. Cell Biol. 217, 3577–3592 (2018).

pubmed: 30087126 pmcid: 6168264

Nixon-Abell, J. et al. Increased spatiotemporal resolution reveals highly dynamic dense tubular matrices in the peripheral ER. Science https://doi.org/10.1126/science.aaf3928 (2016).

doi: 10.1126/science.aaf3928 pubmed: 27789813 pmcid: 6528812

Lee, C. A. & Blackstone, C. ER morphology and endo-lysosomal crosstalk: functions and disease implications. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1865, 158544 (2020).

pubmed: 31678515

Borgese, N., Francolini, M. & Snapp, E. Endoplasmic reticulum architecture: structures in flux. Curr. Opin. Cell Biol. 18, 358–364 (2006).

pubmed: 16806883 pmcid: 4264046

Khaminets, A. et al. Regulation of endoplasmic reticulum turnover by selective autophagy. Nature 522, 354–358 (2015).

pubmed: 26040720

Mochida, K. et al. Receptor-mediated selective autophagy degrades the endoplasmic reticulum and the nucleus. Nature 522, 359–362 (2015).

pubmed: 26040717

Hubner, C. A. & Dikic, I. ER-phagy and human diseases. Cell Death Differ. 27, 833–842 (2020).

pubmed: 31659280

Chen, Q., Teng, J. & Chen, J. ATL3, a cargo receptor for reticulophagy. Autophagy 15, 1465–1466 (2019).

pubmed: 31032711 pmcid: 6613889

Liang, J. R., Lingeman, E., Ahmed, S. & Corn, J. E. Atlastins remodel the endoplasmic reticulum for selective autophagy. J. Cell Biol. 217, 3354–3367 (2018).

pubmed: 30143524 pmcid: 6168278

Chen, Q. et al. ATL3 is a tubular ER-phagy receptor for GABARAP-mediated selective autophagy. Curr. Biol. 29, 846–855.e6 (2019).

pubmed: 30773365

Fregno, I. et al. ER-to-lysosome-associated degradation of proteasome-resistant ATZ polymers occurs via receptor-mediated vesicular transport. EMBO J. https://doi.org/10.15252/embj.201899259 (2018).

doi: 10.15252/embj.201899259 pubmed: 30559329 pmcid: 6331724

Forrester, A. et al. A selective ER-phagy exerts procollagen quality control via a Calnexin-FAM134B complex. EMBO J. https://doi.org/10.15252/embj.201899847 (2019).

doi: 10.15252/embj.201899847 pubmed: 30559329

Jiang, X. et al. FAM134B oligomerization drives endoplasmic reticulum membrane scission for ER-phagy. EMBO J. 39, e102608 (2020).

pubmed: 31930741 pmcid: 7049798

Pleiner, T. et al. WNK1 is an assembly factor for the human ER membrane protein complex. Mol. Cell 81, 2693–2704.e12 (2021).

pubmed: 33964204

Shekarabi, M. et al. Mutations in the nervous system-specific HSN2 exon of WNK1 cause hereditary sensory neuropathy type II. J. Clin. Invest. 118, 2496–2505 (2008).

pubmed: 18521183 pmcid: 2398735

Wang, J. J., Yu, B. & Li, Z. The coexistence of a novel WNK1 variant and a copy number variation causes hereditary sensory and autonomic neuropathy type IIA. BMC Med. Genet. 20, 91 (2019).

pubmed: 31132985 pmcid: 6537375

Loggia, M. L. et al. Carriers of recessive WNK1/HSN2 mutations for hereditary sensory and autonomic neuropathy type 2 (HSAN2) are more sensitive to thermal stimuli. J. Neurosci. 29, 2162–2166 (2009).

pubmed: 19228968 pmcid: 2749662

Izadifar, A. et al. Axon morphogenesis and maintenance require an evolutionary conserved safeguard function of Wnk kinases antagonizing Sarm and Axed. Neuron https://doi.org/10.1016/j.neuron.2021.07.006 (2021).

doi: 10.1016/j.neuron.2021.07.006 pubmed: 34384519

Huang, E. J. & Reichardt, L. F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 24, 677–736 (2001).

pubmed: 11520916 pmcid: 2758233

Bradshaw, R. A. Rita Levi-Montalcini (1909-2012). Nature 493, 306 (2013).

pubmed: 23325208

Shaikh, S. S. et al. A comprehensive functional analysis of NTRK1 missense mutations causing hereditary sensory and autonomic neuropathy type IV (HSAN IV). Hum. Mutat. 38, 55–63 (2017).

pubmed: 27676246

Crowley, C. et al. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 76, 1001–1011 (1994).

pubmed: 8137419

Smeyne, R. J. et al. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature 368, 246–249 (1994).

pubmed: 8145823

Einarsdottir, E. et al. A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum. Mol. Genet. 13, 799–805 (2004).

pubmed: 14976160

Indo, Y. et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat. Genet. 13, 485–488 (1996).

pubmed: 8696348

Carvalho, O. P. et al. A novel NGF mutation clarifies the molecular mechanism and extends the phenotypic spectrum of the HSAN5 neuropathy. J. Med. Genet. 48, 131–135 (2011).

pubmed: 20978020

Shaikh, S. S., Nahorski, M. S. & Woods, C. G. A third HSAN5 mutation disrupts the nerve growth factor furin cleavage site. Mol. Pain. 14, 1744806918809223 (2018).

pubmed: 30296891 pmcid: 6207963

Minde, J. et al. A novel NGFB point mutation: a phenotype study of heterozygous patients. J. Neurol. Neurosurg. Psychiatry 80, 188–195 (2009).

pubmed: 18420729

Cortese, A. et al. Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. Nat. Genet. 51, 649–658 (2019).

pubmed: 30926972 pmcid: 6709527

Rafehi, H. et al. Bioinformatics-based identification of expanded repeats: a non-reference intronic pentamer expansion in RFC1 causes CANVAS. Am. J. Hum. Genet. 105, 151–165 (2019).

pubmed: 31230722 pmcid: 6612533

Tagliapietra, M. et al. RFC1 AAGGG repeat expansion masquerading as chronic idiopathic axonal polyneuropathy. J. Neurol. https://doi.org/10.1007/s00415-021-10552-3 (2021).

doi: 10.1007/s00415-021-10552-3 pubmed: 33884451 pmcid: 8505379

Kumar, K. R. et al. RFC1 expansions can mimic hereditary sensory neuropathy with cough and Sjogren syndrome. Brain 143, e82 (2020).

pubmed: 32949124 pmcid: 7586083

Beijer, D. et al. RFC1 repeat expansions: a recurrent cause of sensory and autonomic neuropathy with cough and ataxia. Eur. J. Neurol. https://doi.org/10.1111/ene.15310 (2022).

doi: 10.1111/ene.15310 pubmed: 35253317

Bennett, D. L., Clark, A. J., Huang, J., Waxman, S. G. & Dib-Hajj, S. D. The role of voltage-gated sodium channels in pain signaling. Physiol. Rev. 99, 1079–1151 (2019).

pubmed: 30672368

Körner, J. & Lampert, A. in The Senses: a Comprehensive Reference 2nd edn Vol. 5 (ed. Fritzsch, B.) 120–141 (Academic, 2020).

Cox, J. J. et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444, 894–898 (2006).

pubmed: 17167479 pmcid: 7212082

Middleton, S. J. et al. Nav1.7 is required for normal C-low threshold mechanoreceptor function in humans and mice. Brain https://doi.org/10.1093/brain/awab482 (2021).

doi: 10.1093/brain/awab482 pubmed: 34957475 pmcid: 9128822

Goldberg, Y. P. et al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin. Genet. 71, 311–319 (2007).

pubmed: 17470132

Weiss, J. et al. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia. Nature 472, 186–190 (2011).

pubmed: 21441906 pmcid: 3674497

McDermott, L. A. et al. Defining the functional role of NaV1.7 in human nociception. Neuron 101, 905–919.e8 (2019).

pubmed: 30795902 pmcid: 6424805

Nassar, M. A. et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc. Natl Acad. Sci. USA 101, 12706–12711 (2004).

pubmed: 15314237 pmcid: 515119

Minett, M. S. et al. Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat. Commun. 3, 791 (2012).

pubmed: 22531176

Minett, M. S. et al. Pain without nociceptors? Nav1.7-independent pain mechanisms. Cell Rep. 6, 301–312 (2014).

pubmed: 24440715 pmcid: 3969273

Shields, S. D. et al. Insensitivity to pain upon adult-onset deletion of Nav1.7 or its blockade with selective inhibitors. J. Neurosci. 38, 10180–10201 (2018).

pubmed: 30301756 pmcid: 6596201

Eagles, D. A., Chow, C. Y. & King, G. F. Fifteen years of NaV 1.7 channels as an analgesic target: why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy? Br. J. Pharmacol. https://doi.org/10.1111/bph.15327 (2020).

doi: 10.1111/bph.15327 pubmed: 33206998

Moreno, A. M. et al. Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aay9056 (2021).

doi: 10.1126/scitranslmed.aay9056 pubmed: 34290053 pmcid: 8456366

Kingwell, K. Nav1.7 withholds its pain potential. Nat. Rev. Drug Discov. https://doi.org/10.1038/d41573-41019-00065-41570 (2019).

doi: 10.1038/d41573-41019-00065-41570 pubmed: 31048807

Pereira, V. et al. Analgesia linked to Nav1.7 loss of function requires micro- and delta-opioid receptors. Wellcome Open Res. 3, 101 (2018).

pubmed: 30271888 pmcid: 6134336

Minett, M. S. et al. Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7. Nat. Commun. 6, 8967 (2015).

pubmed: 26634308

Isensee, J. et al. Synergistic regulation of serotonin and opioid signaling contributes to pain insensitivity in Nav1.7 knockout mice. Sci. Signal. https://doi.org/10.1126/scisignal.aah4874 (2017).

doi: 10.1126/scisignal.aah4874 pubmed: 28074005 pmcid: 6711404

MacDonald, D. I. et al. A central mechanism of analgesia in mice and humans lacking the sodium channel NaV1.7. Neuron 109, 1497–1512.e6 (2021).

pubmed: 33823138 pmcid: 8110947

Bennett, D. L. & Woods, C. G. Painful and painless channelopathies. Lancet Neurol. 13, 587–599 (2014).

pubmed: 24813307

Faber, C. G. et al. Gain of function NaV1.7 mutations in idiopathic small fiber neuropathy. Ann. Neurol. 71, 26–39 (2012).

pubmed: 21698661

Fertleman, C. R. et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52, 767–774 (2006).

pubmed: 17145499

Yang, Y. et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J. Med. Genet. 41, 171–174 (2004).

pubmed: 14985375 pmcid: 1735695

King, M. K., Leipold, E., Goehringer, J. M., Kurth, I. & Challman, T. D. Pain insensitivity: distal S6-segment mutations in NaV1.9 emerge as critical hotspot. Neurogenetics 18, 179–181 (2017).

pubmed: 28289907

Phatarakijnirund, V. et al. Congenital insensitivity to pain: fracturing without apparent skeletal pathobiology caused by an autosomal dominant, second mutation in SCN11A encoding voltage-gated sodium channel 1.9. Bone 84, 289–298 (2016).

pubmed: 26746779

Leipold, E. et al. A de novo gain-of-function mutation in SCN11A causes loss of pain perception. Nat. Genet. 45, 1399–1404 (2013).

pubmed: 24036948

Cox, J. J. & Wood, J. N. No pain, more gain. Nat. Genet. 45, 1271–1272 (2013).

pubmed: 24165728

Woods, C. G., Babiker, M. O., Horrocks, I., Tolmie, J. & Kurth, I. The phenotype of congenital insensitivity to pain due to the NaV1.9 variant p.L811P. Eur. J. Hum. Genet. 23, 561–563 (2015).

pubmed: 25118027

Huang, J. et al. Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy. Brain 137, 1627–1642 (2014).

pubmed: 24776970

Leipold, E. et al. Cold-aggravated pain in humans caused by a hyperactive NaV1.9 channel mutant. Nat. Commun. 6, 10049 (2015).

pubmed: 26645915

Zhang, X. Y. et al. Gain-of-function mutations in SCN11A cause familial episodic pain. Am. J. Hum. Genet. 93, 957–966 (2013).

pubmed: 24207120 pmcid: 3824123

Huang, J. et al. Sodium channel NaV1.9 mutations associated with insensitivity to pain dampen neuronal excitability. J. Clin. Invest. 127, 2805–2814 (2017).

pubmed: 28530638 pmcid: 5490760

Faber, C. G. et al. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc. Natl Acad. Sci. USA 109, 19444–19449 (2012).

pubmed: 23115331 pmcid: 3511073

Kaluza, L. et al. Loss-of-function of Nav1.8/D1639N linked to human pain can be rescued by lidocaine. Pflug. Arch. 470, 1787–1801 (2018).

Kist, A. M. et al. SCN10A mutation in a patient with erythromelalgia enhances C-fiber activity dependent slowing. PLoS ONE 11, e0161789 (2016).

pubmed: 27598514 pmcid: 5012686

Weiss, B. & Stoffel, W. Human and murine serine-palmitoyl-CoA transferase–cloning, expression and characterization of the key enzyme in sphingolipid synthesis. Eur. J. Biochem. 249, 239–247 (1997).

pubmed: 9363775

Bejaoui, K. et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat. Genet. 27, 261–262 (2001).

pubmed: 11242106

Rotthier, A. et al. Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause hereditary sensory and autonomic neuropathy type I. Am. J. Hum. Genet. 87, 513–522 (2010).

pubmed: 20920666 pmcid: 2948807

Auer-Grumbach, M. Hereditary sensory neuropathy type I. Orphanet J. Rare Dis. 3, 7 (2008).

pubmed: 18348718 pmcid: 2311280

Auer-Grumbach, M. et al. Mutations at Ser331 in the HSN type I gene SPTLC1 are associated with a distinct syndromic phenotype. Eur. J. Med. Genet. 56, 266–269 (2013).

pubmed: 23454272 pmcid: 3682180

Rotthier, A. et al. Characterization of two mutations in the SPTLC1 subunit of serine palmitoyltransferase associated with hereditary sensory and autonomic neuropathy type I. Hum. Mutat. 32, E2211–E2225 (2011).

pubmed: 21618344

Penno, A. et al. Hereditary sensory neuropathy type 1 is caused by the accumulation of two neurotoxic sphingolipids. J. Biol. Chem. 285, 11178–11187 (2010).

pubmed: 20097765 pmcid: 2856995

Gantner, M. L. et al. Serine and lipid metabolism in macular disease and peripheral neuropathy. N. Engl. J. Med. 381, 1422–1433 (2019).

pubmed: 31509666 pmcid: 7685488

Mwinyi, J. et al. Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitus. PLoS ONE 12, e0175776 (2017).

pubmed: 28472035 pmcid: 5417440

Dohrn, M. F. et al. Elevation of plasma 1-deoxy-sphingolipids in type 2 diabetes mellitus: a susceptibility to neuropathy? Eur. J. Neurol. 22, 806–e55 (2015).

pubmed: 25623782

Othman, A. et al. Plasma 1-deoxysphingolipids are predictive biomarkers for type 2 diabetes mellitus. BMJ Open Diabetes Res. Care 3, e000073 (2015).

pubmed: 25815206 pmcid: 4368929

Othman, A. et al. Lowering plasma 1-deoxysphingolipids improves neuropathy in diabetic rats. Diabetes 64, 1035–1045 (2015).

pubmed: 25277395

Alecu, I. et al. Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction. J. Lipid Res. 58, 42–59 (2017).

pubmed: 27881717

Wilson, E. R. et al. Hereditary sensory neuropathy type 1-associated deoxysphingolipids cause neurotoxicity, acute calcium handling abnormalities and mitochondrial dysfunction in vitro. Neurobiol. Dis. 117, 1–14 (2018).

pubmed: 29778900 pmcid: 6060082

Clark, A. J. et al. An iPSC model of hereditary sensory neuropathy-1 reveals L-serine-responsive deficits in neuronal ganglioside composition and axoglial interactions. Cell Rep. Med. 2, 100345 (2021).

pubmed: 34337561 pmcid: 8324498

Scherer, S. S. The debut of a rational treatment for an inherited neuropathy? J. Clin. Invest. 121, 4624–4627 (2011).

pubmed: 22045569 pmcid: 3226011

Mohassel, P. et al. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat. Med. 27, 1197–1204 (2021).

pubmed: 34059824

Johnson, J. O. et al. Association of variants in the SPTLC1 gene with juvenile amyotrophic lateral sclerosis. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2021.2598 (2021).

doi: 10.1001/jamaneurol.2021.2598 pubmed: 34459874 pmcid: 8406220

Anderson, S. L. et al. Familial dysautonomia is caused by mutations of the IKAP gene. Am. J. Hum. Genet. 68, 753–758 (2001).

pubmed: 11179021 pmcid: 1274486

Slaugenhaupt, S. A. et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am. J. Hum. Genet. 68, 598–605 (2001).

pubmed: 11179008 pmcid: 1274473

Waszak, S. M. et al. Germline elongator mutations in sonic hedgehog medulloblastoma. Nature 580, 396–401 (2020).

pubmed: 32296180 pmcid: 7430762

Goffena, J. et al. Elongator and codon bias regulate protein levels in mammalian peripheral neurons. Nat. Commun. 9, 889 (2018).

pubmed: 29497044 pmcid: 5832791

Lefcort, F., Mergy, M., Ohlen, S. B., Ueki, Y. & George, L. Animal and cellular models of familial dysautonomia. Clin. Auton. Res. 27, 235–243 (2017).

pubmed: 28667575 pmcid: 5722227

Dietrich, P. & Dragatsis, I. Familial dysautonomia: mechanisms and models. Genet. Mol. Biol. 39, 497–514 (2016).

pubmed: 27561110 pmcid: 5127153

Quigley, J. G. et al. Identification of a human heme exporter that is essential for erythropoiesis. Cell 118, 757–766 (2004).

pubmed: 15369674

Chiabrando, D., Fiorito, V., Petrillo, S., Bertino, F. & Tolosano, E. HEME: a neglected player in nociception? Neurosci. Biobehav. Rev. 124, 124–136 (2021).

pubmed: 33545213

Rajadhyaksha, A. M. et al. Mutations in FLVCR1 cause posterior column ataxia and retinitis pigmentosa. Am. J. Hum. Genet. 87, 643–654 (2010).

pubmed: 21070897 pmcid: 2978959

Chiabrando, D. et al. Mutations in the heme exporter FLVCR1 cause sensory neurodegeneration with loss of pain perception. PLoS Genet. 12, e1006461 (2016).

pubmed: 27923065 pmcid: 5140052

Bertino, F. et al. Heme and sensory neuropathy: insights from novel mutations in the heme exporter feline leukemia virus subgroup C receptor 1. Pain 160, 2766–2775 (2019).

pubmed: 31408049

Grudzinska Pechhacker, M. K. et al. FLVCR1-related disease as a rare cause of retinitis pigmentosa and hereditary sensory autonomic neuropathy. Eur. J. Med. Genet. 63, 104037 (2020).

pubmed: 32822874

Koehler, K. et al. Mutations in GMPPA cause a glycosylation disorder characterized by intellectual disability and autonomic dysfunction. Am. J. Hum. Genet. 93, 727–734 (2013).

pubmed: 24035193 pmcid: 3791256

Gold, W. A. et al. A novel mutation in GMPPA in siblings with apparent intellectual disability, epilepsy, dysmorphism, and autonomic dysfunction. Am. J. Med. Genet. A 173, 2246–2250 (2017).

pubmed: 28574218

Benitez, E. O., Morales, J. J., Munoz, L. A., Hubner, C. A. & Mutchinick, O. M. A novel GMPPA mutation in two adult sisters with achalasia, alacrima, short stature, dysmorphism, and intellectual disability. Mol. Syndromol. 9, 110–114 (2018).

pubmed: 29593478 pmcid: 5836150

Diaz, J., Kane, T. D. & Leon, E. Evidence of GMPPA founder mutation in indigenous Guatemalan population associated with alacrima, achalasia, and mental retardation syndrome. Am. J. Med. Genet. A 182, 425–430 (2020).

pubmed: 31898852

Franzka, P. et al. GMPPA defects cause a neuromuscular disorder with α-dystroglycan hyperglycosylation. J. Clin. Invest. https://doi.org/10.1172/JCI139076 (2021).

doi: 10.1172/JCI139076 pubmed: 33755596 pmcid: 8087212

Zheng, L. et al. Cryo-EM structures of human GMPPA-GMPPB complex reveal how cells maintain GDP-mannose homeostasis. Nat. Struct. Mol. Biol. 28, 1–12 (2021).

pubmed: 33986552

Schneeberger, P. E. et al. Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder. Brain 143, 2437–2453 (2020).

pubmed: 32761064 pmcid: 7447524

Baumann, M. et al. MPV17 mutations in juvenile- and adult-onset axonal sensorimotor polyneuropathy. Clin. Genet. 95, 182–186 (2019).

pubmed: 30298599

Appenzeller, O., Kornfeld, M. & Snyder, R. Acromutilating, paralyzing neuropathy with corneal ulceration in Navajo children. Arch. Neurol. 33, 733–738 (1976).

pubmed: 185990

Johnsen, S. D., Johnson, P. C. & Stein, S. R. Familial sensory autonomic neuropathy with arthropathy in Navajo children. Neurology 43, 1120–1125 (1993).

pubmed: 8170555

Karadimas, C. L. et al. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. Am. J. Hum. Genet. 79, 544–548 (2006).

pubmed: 16909392 pmcid: 1559552

Spinazzola, A. et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat. Genet. 38, 570–575 (2006).

pubmed: 16582910

Heimer, G. et al. TECPR2 mutations cause a new subtype of familial dysautonomia like hereditary sensory autonomic neuropathy with intellectual disability. Eur. J. Paediatr. Neurol. 20, 69–79 (2016).

pubmed: 26542466

Palma, J. A. et al. Expanding the genotypic spectrum of congenital sensory and autonomic neuropathies using whole-exome sequencing. Neurol. Genet. 7, e568 (2021).

pubmed: 33884296 pmcid: 8054964

Neuser, S. et al. Clinical, neuroimaging, and molecular spectrum of TECPR2-associated hereditary sensory and autonomic neuropathy with intellectual disability. Hum. Mutat. 42, 762–776 (2021).

pubmed: 33847017

Covone, A. E. et al. WES in a family trio suggests involvement of TECPR2 in a complex form of progressive motor neuron disease. Clin. Genet. 90, 182–185 (2016).

pubmed: 27406698

Oz-Levi, D. et al. Mutation in TECPR2 reveals a role for autophagy in hereditary spastic paraparesis. Am. J. Hum. Genet. 91, 1065–1072 (2012).

pubmed: 23176824 pmcid: 3516605

Fraiberg, M. et al. Lysosomal targeting of autophagosomes by the TECPR domain of TECPR2. Autophagy 17, 3096–3108 (2021).

pubmed: 33213269

Tamim-Yecheskel, B. C. et al. A tecpr2 knockout mouse exhibits age-dependent neuroaxonal dystrophy associated with autophagosome accumulation. Autophagy 17, 3082–3095 (2021).

pubmed: 33218264

Stadel, D. et al. TECPR2 cooperates with LC3C to regulate COPII-dependent ER export. Mol. Cell 60, 89–104 (2015).

pubmed: 26431026

Patwari, P. P., Wolfe, L. F., Sharma, G. D. & Berry-Kravis, E. TECPR2 mutation-associated respiratory dysregulation: more than central apnea. J. Clin. Sleep. Med. 16, 977–982 (2020).

pubmed: 32209221 pmcid: 7849658

Bouhouche, A., Benomar, A., Bouslam, N., Chkili, T. & Yahyaoui, M. Mutation in the epsilon subunit of the cytosolic chaperonin-containing t-complex peptide-1 (Cct5) gene causes autosomal recessive mutilating sensory neuropathy with spastic paraplegia. J. Med. Genet. 43, 441–443 (2006).

pubmed: 16399879 pmcid: 2564519

Bouhouche, A. et al. Autosomal recessive mutilating sensory neuropathy with spastic paraplegia maps to chromosome 5p15.31-14.1. Eur. J. Hum. Genet. 14, 249–252 (2006).

pubmed: 16333315

Antona, V. et al. A novel CCT5 missense variant associated with early onset motor neuropathy. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21207631 (2020).

doi: 10.3390/ijms21207631 pubmed: 33076433 pmcid: 7589105

Makari, G. S., Carroll, J. E. & Burton, E. M. Hereditary sensory neuropathy manifesting as possible child abuse. Pediatrics 93, 842–844 (1994).

pubmed: 8165095

van den Bosch, G. E. et al. Pain insensitivity syndrome misinterpreted as inflicted burns. Pediatrics 133, e1381–e1387 (2014).

pubmed: 24733875

Marbach, F. et al. Variants in PRKAR1B cause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain. Genet. Med. 23, 1465–1473 (2021).

pubmed: 33833410 pmcid: 8354857

Jinnah, H. A. HPRT1 Disorders. GeneReviews https://www.ncbi.nlm.nih.gov/books/NBK1149/ (updated 6 Aug 2020).

Hepburn, L. et al. Innate immunity. A Spaetzle-like role for nerve growth factor β in vertebrate immunity to Staphylococcus aureus. Science 346, 641–646 (2014).

pubmed: 25359976 pmcid: 4255479

Li, N. et al. Heterogeneity of clinical features and mutation analysis of NTRK1 in Han Chinese patients with congenital insensitivity to pain with anhidrosis. J. Pain. Res. 12, 453–465 (2019).

pubmed: 30774415 pmcid: 6348974

Carroll, A. et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J. Neurol. Neurosurg. Psychiatry https://doi.org/10.1136/jnnp-2021-327909 (2022).

doi: 10.1136/jnnp-2021-327909 pubmed: 35256455

Obici, L. & Mussinelli, R. Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future. Neurotherapeutics 18, 2286–2302 (2021).

pubmed: 34850359

Schwartzlow, C. & Kazamel, M. Hereditary sensory and autonomic neuropathies: adding more to the classification. Curr. Neurol. Neurosci. Rep. 19, 52 (2019).

pubmed: 31222456

De Jonghe, P. K. in Hereditary Peripheral Neuropathies (eds Kuhlenbäumer G., Stögbauer F., Ringelstein E. B., & Young P.) 41–63 (Springer, 2005).

Lauria, G. et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur. J. Neurol. 17, 903–e49 (2010).

pubmed: 20642627

Dyck, P. J. in Peripheral Neuropathy 3rd edn (eds Dyck P. J. et al.) 1065–1093 (Saunders, 1993).

Rolke, R. et al. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur. J. Pain. 10, 77–88 (2006).

pubmed: 16291301

Roberts, R. C. Removing the idiopathic from the chronic sensory neuropathies. Brain 144, 1291–1292 (2021).

pubmed: 33983437 pmcid: 8354263

Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).

pubmed: 32461654 pmcid: 7334197

Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).

pubmed: 27535533 pmcid: 5018207

Boomsma, D. I. et al. The genome of the Netherlands: design, and project goals. Eur. J. Hum. Genet. 22, 221–227 (2014).

pubmed: 23714750

Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).

pubmed: 29165669

Pinero, J. et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 45, D833–D839 (2017).

pubmed: 27924018

Wei, C. H., Allot, A., Leaman, R. & Lu, Z. PubTator central: automated concept annotation for biomedical full text articles. Nucleic Acids Res. 47, W587–W593 (2019).

pubmed: 31114887 pmcid: 6602571

Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607–D613 (2019).

pubmed: 30476243

Consortium, G. T. The GTEx consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318–1330 (2020).

Schwarz, J. M., Rodelsperger, C., Schuelke, M. & Seelow, D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat. Methods 7, 575–576 (2010).

pubmed: 20676075

Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010).

pubmed: 20354512 pmcid: 2855889

Vaser, R., Adusumalli, S., Leng, S. N., Sikic, M. & Ng, P. C. SIFT missense predictions for genomes. Nat. Protoc. 11, 1–9 (2016).

pubmed: 26633127

Jagadeesh, K. A. et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. Nat. Genet. 48, 1581–1586 (2016).

pubmed: 27776117

Heyne, H. O. et al. Predicting functional effects of missense variants in voltage-gated sodium and calcium channels. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aay6848 (2020).

doi: 10.1126/scitranslmed.aay6848 pubmed: 32801145

Kopanos, C. et al. VarSome: the human genomic variant search engine. Bioinformatics 35, 1978–1980 (2019).

pubmed: 30376034

Holtgrewe, M. et al. VarFish: comprehensive DNA variant analysis for diagnostics and research. Nucleic Acids Res. 48, W162–W169 (2020).

pubmed: 32338743 pmcid: 7319464

Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405–424 (2015).

pubmed: 25741868 pmcid: 4544753

Matthijs, G. et al. Guidelines for diagnostic next-generation sequencing. Eur. J. Hum. Genet. 24, 2–5 (2016).

pubmed: 26508566

Kobren, S. N. et al. Commonalities across computational workflows for uncovering explanatory variants in undiagnosed cases. Genet. Med. https://doi.org/10.1038/s41436-020-01084-8 (2021).

doi: 10.1038/s41436-020-01084-8 pubmed: 33580225 pmcid: 8187147

Bis-Brewer, D. M. et al. Assessing non-Mendelian inheritance in inherited axonopathies. Genet. Med. 22, 2114–2119 (2020).

pubmed: 32741968 pmcid: 7710562

Kurth, I. et al. Whole exome sequencing in congenital pain insensitivity identifies a novel causative intronic NTRK1-mutation due to uniparental disomy. Am. J. Med. Genet. B Neuropsychiatr. Genet. 171, 875–878 (2016).

pubmed: 27184211

Li, L. et al. Novel gross deletion mutations in NTRK1 gene associated with congenital insensitivity to pain with anhidrosis. Front. Pediatr. 9, 638190 (2021).

pubmed: 33748046 pmcid: 7969531

Marchi, M. et al. Congenital insensitivity to pain: a novel mutation affecting a U12-type intron causes multiple aberrant splicing of SCN9A. Pain https://doi.org/10.1097/j.pain.0000000000002535 (2021).

doi: 10.1097/j.pain.0000000000002535 pubmed: 34799533

Geng, X. et al. Novel NTRK1 mutations in Chinese patients with congenital insensitivity to pain with anhidrosis. Mol. Pain. 14, 1744806918781140 (2018).

pubmed: 29770739 pmcid: 6009080

GATK Team. (How to) Call common and rare germline copy number variants. GATK https://gatk.broadinstitute.org/hc/en-us/articles/360035531152–How-to-Call-common-and-rare-germline-copy-number-variants (2022).

Kraft, F. & Kurth, I. Long-read sequencing to understand genome biology and cell function. Int. J. Biochem. Cell Biol. 126, 105799 (2020).

pubmed: 32629027

Axelrod, F. B. Familial dysautonomia: a review of the current pharmacological treatments. Expert. Opin. Pharmacother. 6, 561–567 (2005).

pubmed: 15934882

Bar-On, E. et al. Orthopaedic manifestations of familial dysautonomia. A review of one hundred and thirty-six patients. J. Bone Jt. Surg. Am. 82, 1563–1570 (2000).

Kayani, B. et al. Orthopaedic manifestations of congenital indifference to pain with anhidrosis (hereditary sensory and autonomic neuropathy type IV). Eur. J. Paediatr. Neurol. 21, 318–326 (2017).

pubmed: 27637569

Bar-On, E. et al. Congenital insensitivity to pain. Orthopaedic manifestations. J. Bone Jt. Surg. Br. 84, 252–257 (2002).

Loh, J., Cyr, K. & Martin, R. Ankle fracture in hereditary sensory neuropathy type 1. J. Foot Ankle Surg. 60, 621–625 (2021).

pubmed: 33509718

Auer-Grumbach, M. Hereditary sensory and autonomic neuropathies. Handb. Clin. Neurol. 115, 893–906 (2013).

pubmed: 23931820

Fruchtman, Y., Perry, Z. H. & Levy, J. Morbidity characteristics of patients with congenital insensitivity to pain with anhidrosis (CIPA). J. Pediatr. Endocrinol. Metab. 26, 325–332 (2013).

pubmed: 23744299

Weingarten, T. N. et al. Anesthesia and patients with congenital hyposensitivity to pain. Anesthesiology 105, 338–345 (2006).

pubmed: 16871068

Ngai, J., Kreynin, I., Kim, J. T. & Axelrod, F. B. Anesthesia management of familial dysautonomia. Paediatr. Anaesth. 16, 611–620 (2006).

pubmed: 16719876

Zlotnik, A. et al. Anesthetic management of patients with congenital insensitivity to pain with anhidrosis: a retrospective analysis of 358 procedures performed under general anesthesia. Anesth. Analg. 121, 1316–1320 (2015).

pubmed: 26484462 pmcid: 4663042

Ozmete, O., Sener, M., Bali, C., Caliskan, E. & Aribogan, A. Congenital insensitivity to pain: how should anesthesia be managed? Turk. J. Pediatr. 59, 87–89 (2017).

pubmed: 29168371

Weingarten, T. N., Sprung, J. & Burgher, A. H. Perioperative management of familial dysautonomia: a systematic review. Eur. J. Anaesthesiol. 24, 309–316 (2007).

pubmed: 17202006

Elhennawy, K. et al. Oral manifestations, dental management, and a rare homozygous mutation of the PRDM12 gene in a boy with hereditary sensory and autonomic neuropathy type VIII: a case report and review of the literature. J. Med. Case Rep. 11, 233 (2017).

pubmed: 28807049 pmcid: 5556355

Axelrod, F. B. & Berlin, D. Pregabalin: a new approach to treatment of the dysautonomic crisis. Pediatrics 124, 743–746 (2009).

pubmed: 19620195

Norcliffe-Kaufmann, L., Martinez, J., Axelrod, F. & Kaufmann, H. Hyperdopaminergic crises in familial dysautonomia: a randomized trial of carbidopa. Neurology 80, 1611–1617 (2013).

pubmed: 23553478 pmcid: 3662326

Norcliffe-Kaufmann, L., Palma, J. A., Martinez, J. & Kaufmann, H. Carbidopa for afferent baroreflex failure in familial dysautonomia: a double-blind randomized crossover clinical trial. Hypertension 76, 724–731 (2020).

pubmed: 32654554

Spalink, C. L., Barnes, E., Palma, J. A., Norcliffe-Kaufmann, L. & Kaufmann, H. Intranasal dexmedetomidine for adrenergic crisis in familial dysautonomia. Clin. Auton. Res. 27, 279–282 (2017).

pubmed: 28674865 pmcid: 5555081

Shirazi, E., Sayyahfar, S., Motamed, M. & Alaghband-Rad, J. A case of congenital insensitivity to pain with anhidrosis comorbid with attention deficit hyperactivity disorder: clinical implications for pathophysiology and treatment. J. Nerv. Ment. Dis. 206, 296–299 (2018).

pubmed: 29595626

de Greef, B. T. A. et al. Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial. Brain 142, 263–275 (2019).

pubmed: 30649227

Colloca, L. et al. Neuropathic pain. Nat. Rev. Dis. Prim. 3, 17002 (2017).

pubmed: 28205574

Di Stefano, G., Di Lionardo, A., Di Pietro, G., Cruccu, G. & Truini, A. Pharmacotherapeutic options for managing neuropathic pain: a systematic review and meta-analysis. Pain. Res. Manag. 2021, 6656863 (2021).

pubmed: 33986899 pmcid: 8093054

Yozu, A. et al. Hereditary sensory and autonomic neuropathy types 4 and 5: review and proposal of a new rehabilitation method. Neurosci. Res. 104, 105–111 (2016).

pubmed: 26562335

Missaoui, B. & Thoumie, P. Balance training in ataxic neuropathies. Effects on balance and gait parameters. Gait Posture 38, 471–476 (2013).

pubmed: 23465318

Garofalo, K. et al. Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J. Clin. Invest. 121, 4735–4745 (2011).

pubmed: 22045570 pmcid: 3225995

Fridman, V. et al. Randomized trial of L-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology 92, e359–e370 (2019).

pubmed: 30626650 pmcid: 6345118

Auranen, M. et al. Clinical and metabolic consequences of L-serine supplementation in hereditary sensory and autonomic neuropathy type 1C. Cold Spring Harb. Mol. Case Stud. https://doi.org/10.1101/mcs.a002212 (2017).

doi: 10.1101/mcs.a002212 pubmed: 29042446 pmcid: 5701299

Bode, H. et al. HSAN1 mutations in serine palmitoyltransferase reveal a close structure-function-phenotype relationship. Hum. Mol. Genet. 25, 853–865 (2016).

pubmed: 26681808

Yang, H., Brown, R. H. Jr, Wang, D., Strauss, K. A. & Gao, G. AAV-mediated gene therapy for glycosphingolipid biosynthesis deficiencies. Trends Mol. Med. 27, 520–523 (2021).

pubmed: 33714697 pmcid: 8840833

Morini, E. et al. ELP1 splicing correction reverses proprioceptive sensory loss in familial dysautonomia. Am. J. Hum. Genet. 104, 638–650 (2019).

pubmed: 30905397 pmcid: 6451698

Palma, J. A. et al. Current treatments in familial dysautonomia. Expert. Opin. Pharmacother. 15, 2653–2671 (2014).

pubmed: 25323828 pmcid: 4236240

Yannai, S., Zonszain, J., Donyo, M. & Ast, G. Combinatorial treatment increases IKAP levels in human cells generated from familial dysautonomia patients. PLoS ONE 14, e0211602 (2019).

pubmed: 30889183 pmcid: 6424424

Sinha, R. et al. Antisense oligonucleotides correct the familial dysautonomia splicing defect in IKBKAP transgenic mice. Nucleic Acids Res. 46, 4833–4844 (2018).

pubmed: 29672717 pmcid: 6007753

Bonne, G. The Treatabolome, an emerging concept. J. Neuromuscul. Dis. 8, 337–339 (2021).

pubmed: 33935101 pmcid: 8203244

Aarestrup, F. M. et al. Towards a European health research and innovation cloud (HRIC). Genome Med. 12, 18 (2020).

pubmed: 32075696 pmcid: 7029532

Jennings, M. J., Lochmuller, A., Atalaia, A. & Horvath, R. Targeted therapies for hereditary peripheral neuropathies: systematic review and steps towards a ‘treatabolome’. J. Neuromuscul. Dis. 8, 383–400 (2021).

pubmed: 32773395 pmcid: 8203235

Kugathasan, U. et al. Development of MRC centre MRI calf muscle fat fraction protocol as a sensitive outcome measure in hereditary sensory neuropathy type 1. J. Neurol. Neurosurg. Psychiatry 90, 895–906 (2019).

pubmed: 30995999

Schrenk-Siemens, K. et al. PIEZO2 is required for mechanotransduction in human stem cell-derived touch receptors. Nat. Neurosci. 18, 10–16 (2015).

pubmed: 25469543

Middleton, S. J. et al. Studying human nociceptors: from fundamentals to clinic. Brain 144, 1312–1335 (2021).

pubmed: 34128530 pmcid: 8219361

Chambers, S. M. et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat. Biotechnol. 30, 715–720 (2012).

pubmed: 22750882 pmcid: 3516136

Nickolls, A. R. et al. Transcriptional programming of human mechanosensory neuron subtypes from pluripotent stem cells. Cell Rep. 30, 932–946.e7 (2020).

pubmed: 31968264 pmcid: 7059559

Namer, B. et al. Pain relief in a neuropathy patient by lacosamide: proof of principle of clinical translation from patient-specific iPS cell-derived nociceptors. EBioMedicine 39, 401–408 (2019).

pubmed: 30503201

Lampert, A. et al. Human sensory neurons derived from pluripotent stem cells for disease modelling and personalized medicine. Neurobiol. Pain. 8, 100055 (2020).

pubmed: 33364527 pmcid: 7750732

Zeidler, M. et al. NOCICEPTRA: gene and microRNA signatures and their trajectories characterizing human iPSC-derived nociceptor maturation. Adv. Sci. 8, e2102354 (2021).

Eberhardt, E. et al. Pattern of functional TTX-resistant sodium channels reveals a developmental stage of human iPSC- and ESC-derived nociceptors. Stem Cell Rep. 5, 305–313 (2015).

Clark, A. J. et al. Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination. Brain 140, 898–913 (2017).

pubmed: 28334857 pmcid: 5637940

Pereira, J. D. et al. Human sensorimotor organoids derived from healthy and amyotrophic lateral sclerosis stem cells form neuromuscular junctions. Nat. Commun. 12, 4744 (2021).

pubmed: 34362895 pmcid: 8346474

Sharma, A., Sances, S., Workman, M. J. & Svendsen, C. N. Multi-lineage human iPSC-derived platforms for disease modeling and drug discovery. Cell Stem Cell 26, 309–329 (2020).

pubmed: 32142662 pmcid: 7159985

Tavares-Ferreira, D. et al. Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors. Sci. Transl. Med. 14, eabj8186 (2022).

pubmed: 35171654

Haring, M. et al. Neuronal atlas of the dorsal horn defines its architecture and links sensory input to transcriptional cell types. Nat. Neurosci. 21, 869–880 (2018).

pubmed: 29686262

Kupari, J. et al. Single cell transcriptomics of primate sensory neurons identifies cell types associated with chronic pain. Nat. Commun. 12, 1510 (2021).

pubmed: 33686078 pmcid: 7940623

Nguyen, M. Q., von Buchholtz, L. J., Reker, A. N., Ryba, N. J. & Davidson, S. Single-nucleus transcriptomic analysis of human dorsal root ganglion neurons. eLife https://doi.org/10.7554/eLife.71752 (2021).

doi: 10.7554/eLife.71752 pubmed: 34825887 pmcid: 8626086

Sathyamurthy, A. et al. Massively parallel single nucleus transcriptional profiling defines spinal cord neurons and their activity during behavior. Cell Rep. 22, 2216–2225 (2018).

pubmed: 29466745 pmcid: 5849084

Usoskin, D. et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat. Neurosci. 18, 145–153 (2015).

pubmed: 25420068

Vega-Loza, A., Van, C., Moreno, A. M. & Aleman, F. Gene therapies to reduce chronic pain: are we there yet? Pain. Manag. 10, 209–212 (2020).

pubmed: 32677877

Mullard, A. Gene therapy community grapples with toxicity issues, as pipeline matures. Nat. Rev. Drug Discov. 20, 804–805 (2021).

pubmed: 34599291

Just, S. & Buning, H. Key to delivery: the (epi-)genome editing vector toolbox. Methods Mol. Biol. 1767, 147–166 (2018).

pubmed: 29524133

Tracey, I. & Mantyh, P. W. The cerebral signature for pain perception and its modulation. Neuron 55, 377–391 (2007).

pubmed: 17678852

Ossipov, M. H., Morimura, K. & Porreca, F. Descending pain modulation and chronification of pain. Curr. Opin. Support. Palliat. Care 8, 143–151 (2014).

pubmed: 24752199 pmcid: 4301419

Schrenk-Siemens, K. et al. HESC-derived sensory neurons reveal an unexpected role for PIEZO2 in nociceptor mechanotransduction. Preprint at bioRxiv https://doi.org/10.1101/741660 (2019).

doi: 10.1101/741660

Richter, T. et al. Rare disease terminology and definitions–a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health 18, 906–914 (2015).

pubmed: 26409619

Nahin, R. L. Estimates of pain prevalence and severity in adults: United States, 2012. J. Pain. 16, 769–780 (2015).

pubmed: 26028573 pmcid: 4562413

Stoicea, N. et al. Current perspectives on the opioid crisis in the US healthcare system: a comprehensive literature review. Medicine 98, e15425 (2019).

pubmed: 31096439 pmcid: 6531094

Sexton, J. E., Cox, J. J., Zhao, J. & Wood, J. N. The genetics of pain: implications for therapeutics. Annu. Rev. Pharmacol. Toxicol. 58, 123–142 (2018).

pubmed: 28968191

Miller, R. E., Block, J. A. & Malfait, A. M. What is new in pain modification in osteoarthritis? Rheumatology 57, iv99–iv107 (2018).

pubmed: 29361112 pmcid: 5905627

Brown, M. T. et al. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J. Pain. 13, 790–798 (2012).

pubmed: 22784777

Journal

Informations de publication

Résumé

Identifiants

Types de publication

Langues

Sous-ensembles de citation

Pagination

Subventions

Informations de copyright

Références

Auteurs

Articles similaires

Classifications MeSH